Print  |  Close

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Active: Yes
Cancer Type: Lymphoma NCT ID: NCT05776160
Trial Phases: Protocol IDs: KT-US-471-0140 (primary)
Eligibility: 18 Years and older (Adult, Older Adult ), Male and Female Study Type: Treatment
Study Sponsor: Gilead Sciences (Kite, A Gilead Company)
NCI Full Details: https://clinicaltrials.gov/study/NCT05776160

Summary

The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.

Drug: Axicabtagene Ciloleucel

  • A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.

  • Other Names:
    • Yescarta®

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523


**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.